Depression treatment has genuinely changed over the past decade, and for men who have tried two or three antidepressants without much benefit, that matters. It also means the subject now attracts an enormous amount of coverage, much of it produced by people selling something. Sorting the two apart is difficult from the outside, particularly when the language used by a legitimate clinical trial and by a private clinic advertising infusions can sound very similar.
A reasonable starting point is that treatment-resistant depression — depression that has not responded to adequate trials of standard treatment — is common, and it is a legitimate reason to look beyond the first line. It is also a diagnosis that should be arrived at properly, because a substantial number of men labelled treatment-resistant were in fact undertreated: too low a dose, too short a trial, an untreated thyroid problem, ongoing heavy alcohol use, undiagnosed sleep apnoea, or an underlying bipolar disorder that antidepressants alone will not address. Establishing that before moving to newer treatments is not a delaying tactic; it frequently resolves the problem.
What Has Solid Evidence
Ketamine and its derivative esketamine are the most substantial development. Unlike conventional antidepressants, which act on serotonin and noradrenaline over weeks, ketamine works on the glutamate system and can produce improvement within hours to days — including reduction in suicidal thinking, which is clinically significant in a way that is hard to overstate. Esketamine is approved in Canada as a nasal spray for treatment-resistant depression, given under supervision in a clinical setting because of dissociative effects and blood pressure changes.
The caveats are real. The effect wears off, so repeated treatment is required to sustain it. Long-term data are still accumulating. Ketamine has abuse potential and bladder toxicity with heavy repeated use, and the private infusion market operating with variable oversight is a genuine concern. Supervised delivery through a proper programme is not the same thing as an infusion clinic.
Repetitive transcranial magnetic stimulation, or rTMS, uses magnetic pulses to stimulate a region of the frontal cortex. It is non-invasive, does not require sedation, and has a solid evidence base for treatment-resistant depression. The main obstacles are practical: it requires daily sessions over several weeks at a centre that offers it, which is a real barrier from this part of the province.
Electroconvulsive therapy deserves mention precisely because its reputation is so poor. Modern ECT is delivered under general anaesthetic with muscle relaxation, and it remains the most effective treatment available for severe depression, particularly with psychotic features or where a person is not eating. Memory effects around the treatment period are real and usually temporary. It has essentially nothing in common with what people picture.
What Remains Experimental
Psilocybin and MDMA-assisted therapy generate the most headlines and have the least settled evidence. Early trials have been promising, but they involve carefully selected participants, extensive preparatory and integration therapy, and controlled settings — none of which resembles taking mushrooms independently. Regulatory access in Canada is limited to specific pathways. Anyone considering this should know that psychedelics can precipitate psychosis in people with a predisposition and can interact badly with existing psychiatric medication.
Supplements and devices marketed for depression range from mildly supported to entirely unsupported. Anything promising a cure, quoting dramatic response rates, or requiring substantial up-front payment warrants scepticism.
What Still Does Most of the Work
The unglamorous elements remain the backbone. An adequate trial of a standard antidepressant at a proper dose for a proper duration helps the majority of people. Structured psychotherapy has evidence comparable to medication for many, and combining the two outperforms either alone. Exercise has real antidepressant effect. Treating sleep apnoea, alcohol use, chronic pain and thyroid disease frequently resolves what looked like resistant depression.
Anyone with thoughts of suicide or self-harm should not wait for the next appointment. Call 911 in an emergency, and the 988 Suicide Crisis Helpline is available anywhere in Canada by call or text, at any hour.
Dr. Isaac Klein assesses and treats depression, including difficult-to-treat depression, at Grande Prairie Men’s Medical Clinic, and can advise on which options are appropriate and accessible. Appointments can be made at gpmm.clinic or by calling (587) 416-8296. This article is general information and does not replace an individual psychiatric assessment.